Opinion|Videos|November 16, 2026

Dual BAFF/APRIL Inhibition in IgAN: ORIGIN 3 Data and Open Questions

ORIGIN 3 results for dual BAFF/APRIL inhibition look similar to selective APRIL blockade. The panel asks what could separate the two, from durability and dosing to what happens when therapy stops.

Dr. Wadhwani frames the question by connecting VISIONARY, which tested selective APRIL inhibition, with ORIGIN 3, which tested dual APRIL and BAFF inhibition with atacicept. Dr. Cheung recaps the results. At nine months, 24-hour proteinuria fell 45.7 percent with atacicept versus 6.8 percent with placebo. Mean eGFR change at 52 weeks was about minus 0.1 mL/min with atacicept versus minus 5.7 with placebo. Across 104 weeks, the annualized slope was minus 0.6 versus minus 5.6, well within the guideline target. Dr. Cheung sees the two-year data as broadly similar to selective APRIL inhibition and, in this view, close to equivalent.

Dr. Wadhwani highlights that the sponsor discussed with the FDA moving the final analysis from 104 weeks to 52 weeks. Both timepoints were presented, but the earlier analysis let patients still on placebo cross over to active drug. She argues placebo-controlled trials are becoming harder to justify given how quickly placebo patients decline.

Asked what could differentiate the agents, Dr. Cheung wants to know how durable the effects are, how safe treatment is beyond two years, and how long therapy should continue. Planning treatment breaks, monitoring afterward, and deciding when to restart will matter. Dr. Wadhwani points to telitacicept data from China, where full dosing for nine months was followed by a reduced dose, and to phase 2 data showing rebound of proteinuria and galactose-deficient IgA1 after stopping. Dr. Cheung expects an individualized approach, with some patients able to extend dosing intervals and others not, and calls for capturing real-world experience.

In "B-Cell Biologic Safety in IgAN: Monitoring and Patient Selection," Dr. Geara and Dr. Cheung will explain how they monitor these agents and which patients they consider good candidates.

Related to this article